TRANSDERMAL SKIN PATCHES MARKET ANALYSIS

Drug failure and recalls of transdermal drug delivery systems is expected to hamper the growth of the transdermal skin patches market over the forecast period. For instance, in November 2021, Teva Pharmaceutical Industries Ltd., a pharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) recalled a single lot of clonidine transdermal patches for failing to meet impurities/degradation specifications.

Market Opportunities – Development of Smart and Interactive Transdermal Patches

The development of smart and interactive transdermal patches offers promising opportunities for growth in the global transdermal skin patches market. These next-generation patches go beyond basic transdermal drug delivery by incorporating advanced technologies that allow for real-time patient monitoring and feedback. Smart transdermal patches are embedded with miniaturized sensors, electronics, and communication capabilities. This allows them to passively collect various biomarker data from the skin, such as temperature, hydration levels, glucose concentrations, and others. The collected data can provide medical insights in real-time and be transmitted wirelessly to doctors or caregivers. For patients with chronic conditions like diabetes and cardiac disorders, this added level of round-the-clock monitoring can help manage their care more proactively and prevent critical complications.